15 search results
Breast
22CHA436: Phase II trial to evaluate immune-related biomarkers for pathological response in stage II-III HER2-positive breast cancer receiving neoadjuvant chemotherapy with subsequent randomization to multi-epitope HER2 vaccine vs. placebo in patients wit
Location: Lebanon
22CHA800: Genetically-Informed Therapy for ER+ Breast Cancer in a Post-CDK4/6 Inhibitor Setting: A Phase II Umbrella Study (GERTRUDE)
Location: Lebanon
22SCH740: Phase II Study of Estradiol Therapy to Target ER-Mutant and ER-Wild-Type ER+ Metastatic or Advanced Breast Cancer (ESTHER)
Location: Lebanon
22VAH835: A Phase 3, Randomized, Open-Label, Multicenter Trial of ARV-471 (PF-07850327) vs Fulvestrant in Participants with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer whose Disease Progressed After Prior Endocrine Based Treated for A
Location: Lebanon
A Pilot Study to validate the combined Automated Whole Breast Ultrasound (ABUS) and Electrical Impedance Tomography (EIT) system in breast-biopsy subjects
Location: Lebanon
A Randomized Two-Arm Proof of Concept Study Testing a Novel Approach to Exercise Promotion Based on Affect-regulation
Location: Lebanon
A011801: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tuca
Location: Lebanon
CCTG MA.39 - Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer
Location: Lebanon, St. Johnsbury, VT
Increasing physical activity among breast cancer survivors: Use of the ORBIT Model to refine and test a novel approach to exercise promotion based on affect-regulation
Location: Lebanon
Increasing physical activity among breast cancer survivors: Use of the ORBIT Model to refine and test a novel approach to exercise promotion based on affect-regulation
Location: Lebanon
NRG-BR007: A Phase III Clinical Trial Evaluating DE-escalation of Breast RAdiation (DEBRA) for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score [less than or equal to] 18 Breast Cancer
Location: Lebanon, St. Johnsbury, VT
NRG-BR008: A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer (HERO)
Location: Lebanon
NRG-BR009: A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score =
Location: Lebanon
Randomized phase 2 clinical trial of nab-paclitaxel + durvalumab (MEDI4736) + tremelimumab + neoantigen vaccine vs. nab-paclitaxel + durvalumab (MEDI4736) + tremelimumab in patients with metastatic triple negative breast cancer
Location: Lebanon
S2012 : Randomized Phase II/III Trial of first line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Location: Lebanon, St. Johnsbury, VT